Anzeige
Mehr »
Lynx Broker
Login
Sonntag, 20.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 4489 ISIN: BE0974289218 Ticker-Symbol:  
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ASIT BIOTECH SA Chart 1 Jahr
5-Tage-Chart
ASIT BIOTECH SA 5-Tage-Chart

Aktuelle News zur ASIT BIOTECH Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoASIT Biotech: ASIT biotech Mode of Action Study of gp-ASIT+ for Grass Pollen Allergy Published in The Journal ...2
DoASIT biotech mode of action study of gp-ASIT+ for grass pollen allergy published in The Journal of Allergy and Clinical Immunology (JACI)1173Data show how gp-ASIT+, administered in a pre-seasonal 3-week treatment, is able to rapidly modulate the cellular response and induce production of blocking antibodies. This effect led to a significant...
► Artikel lesen
07.10.ASIT biotech Receives GMP Certification1
Börsennews zur ASIT BIOTECH Aktie und weiteren Hot Stocks erhalten
07.10.ASIT Biotech: ASIT biotech Receives GMP Certification for its Manufacturing Site in Liège, Belgium2
07.10.ASIT biotech receives GMP certification for its manufacturing site in Liège, Belgium272Regulatory News: ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough...
► Artikel lesen
03.10.ASIT biotech: Information on the Total Number of Voting Rights and Shares205Regulatory News: ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough...
► Artikel lesen
26.09.ASIT Biotech: ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy2
26.09.ASIT biotech firmly on course for readout of Phase III clinical study in grass pollen allergy243The Company has passed the Last Patient Last Visit (LPLV) milestone in the pivotal gp-ASIT+ Phase III trial and remains on track to deliver primary efficacy results in December 2019. ASIT...
► Artikel lesen
19.09.ASIT biotech - Building to a crescendo150Having reported H119 financials, ASIT's main focus remains on the results of the second Phase III study of gp-ASIT+ for the prevention of grass pollen allergy. These are expected towards the end of...
► Artikel lesen
18.09.ASIT biotech presents its 2019 half year results and provides further update on its clinical programs until end-2019302Cash position of €2.5 million as of 30 June 2019, reinforced in July 2019 by the private placement of Convertible Notes for a total amount of 9.2 million out of which 5.0 million was paid immediately...
► Artikel lesen
10.09.ASIT biotech Conference Calendar H2 2019304Regulatory News: ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough...
► Artikel lesen
05.09.ASIT Biotech: Successful Pollen Season Confirms ASIT biotech On Track for Phase III Results of gp-ASIT+ in December ...3
05.09.Successful Pollen Season Confirms ASIT biotech on Track for Phase III Results of gp-ASIT+ in December 2019244End of pollen season reached in all sites, allowing for last subject visits according to plan Vaccine industry veteran Beatrice De Vos, MD, to join ASIT biotech as Chief Medical Officer ...
► Artikel lesen
01.08.ASIT biotech: Information on the Total Number of Voting Rights and Shares43Regulatory News: ASIT biotech (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy...
► Artikel lesen
22.07.ASIT Biotech: ASIT biotech Raises EUR 9.225 Million in a Private Placement of Convertible Notes3
22.07.ASIT biotech Raises EUR 9.225 Million in a Private Placement of Convertible Notes33Regulatory News: NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER...
► Artikel lesen
18.07.ASIT biotech Announces the Launch of a Private Placement of Convertible Notes53NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT...
► Artikel lesen
04.07.ASIT biotech: Information on the Total Number of Voting Rights and Shares504Regulatory News: ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough...
► Artikel lesen
01.07.ASIT biotech Continues Its Transformation From Research to Late Stage Clinical Development42Company shareholders approve all motions at Extraordinary General Meeting Firm expects to raise €9-12 M to finance focused development Jean-Paul Prieels confirmed as new member of Board...
► Artikel lesen
24.06.Long-term investors look for stability, which India has: Asit Bhatia2
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1